Agenus reported a net income of $177 million, or $0.76 per share basic and $0.72 per share diluted, and ended the quarter with $262 million in cash and short-term investments. The company also highlighted clinical responses achieved with AGEN1181, the launch of MiNK Therapeutics' IPO, and the launch of its adjuvant business, SaponiQx.
AGEN1181 shows clinical benefit in 9 cold and treatment-resistant tumor types.
MiNK Therapeutics launched an IPO and is trading on NASDAQ.
SaponiQx launch to accelerate development of proven and novel adjuvants.
First patients dosed in multiple collaborator programs.
Analyze how earnings announcements historically affect stock price performance